Intraductal Carcinoma of the Prostate: Indicator of Aggressive Disease

Grant number: 1077799 | Funding period: 2015 - 2018

Completed

Abstract

This proposal addresses the need to improve personalised treatment decisions for men with high risk familial prostate cancer as they have a very aggressive disease progression with a very poor clinical outcome. We will perform biological and pre-clinical studies to improve the clinical diagnosis, prognosis and treatment options for men with germline mutations in BRCA2 or BRCA1 genes who develop prostate cancer.

Related publications (6)

Scholarly works icon

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

GP Risbridger, AK Clark, LH Porter, R Toivanen, A Bakshi, NL Lister, D Pook, CJ Pezaro, S Sandhu, S Keerthikumar, R Quezada Urban, M Papargiris, J Kraska, HB Madsen, H Wang, MG Richards, B Niranjan, S O’Dea, L Teng, W Wheelahan

2021-12-01

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-d..

Scholarly works icon

Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer

LH Porter, A Bakshi, D Pook, A Clark, D Clouston, J Kourambas, DL Goode, GP Risbridger, RA Taylor, MG Lawrence

2021-06-01

Amplifications of the androgen receptor (AR) occur in up to 80% of men with castration-resistant prostate cancer (CRPC). Recent st..

Scholarly works icon

Knowing what's growing: Why ductal and intraductal prostate cancer matter

MG Lawrence, LH Porter, D Clouston, DG Murphy, M Frydenberg, RA Taylor, GP Risbridger

2020-03-04

Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical..

Scholarly works icon

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer

LH Porter, MG Lawrence, H Wang, AK Clark, A Bakshi, D Obinata, D Goode, M Papargiris, null Mural, D Clouston, A Ryan, S Norden, E Corey, PS Nelson, JT Isaacs, J Grummet, J Kourambas, S Sandhu, DG Murphy, D Pook

2019-08-01

Background: Serially transplantable patient-derived xenografts (PDXs) are invaluable preclinical models for studying tumor biology..

Scholarly works icon

The influence of BRCA2 mutation on localized prostate cancer

RA Taylor, M Fraser, RJ Rebello, PC Boutros, DG Murphy, RG Bristow, GP Risbridger

2019-05-01

A key challenge in the management of localized prostate cancer is the identification of men with a high likelihood of progression ..

Scholarly works icon

Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories

LH Porter, MG Lawrence, D Ilic, D Clouston, DM Bolton, M Frydenberg, DG Murphy, C Pezaro, GP Risbridger, RA Taylor

2017-10-01

Intraductal carcinoma of the prostate (IDC-P) is associated with poor prognosis. While it is often regarded as a rare pathology, t..

University of Melbourne Researchers